A detailed history of Gsa Capital Partners LLP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 233,560 shares of TSHA stock, worth $362,018. This represents 0.04% of its overall portfolio holdings.

Number of Shares
233,560
Previous 141,805 64.71%
Holding current value
$362,018
Previous $318,000 47.48%
% of portfolio
0.04%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$2.01 - $2.46 $184,427 - $225,717
91,755 Added 64.71%
233,560 $469,000
Q2 2024

Aug 15, 2024

BUY
$2.04 - $4.17 $289,282 - $591,326
141,805 New
141,805 $318,000
Q2 2023

Aug 14, 2023

SELL
$0.59 - $0.87 $5,463 - $8,057
-9,261 Reduced 33.88%
18,077 $11,000
Q1 2023

May 12, 2023

SELL
$0.65 - $2.3 $101,737 - $359,993
-156,519 Reduced 85.13%
27,338 $21,000
Q4 2022

Feb 13, 2023

SELL
$1.39 - $2.98 $72,645 - $155,743
-52,263 Reduced 22.13%
183,857 $416,000
Q3 2022

Nov 14, 2022

BUY
$1.76 - $4.94 $87,366 - $245,221
49,640 Added 26.62%
236,120 $456,000
Q2 2022

Aug 09, 2022

BUY
$2.47 - $6.77 $171,346 - $469,641
69,371 Added 59.24%
186,480 $694,000
Q1 2022

May 11, 2022

BUY
$5.22 - $11.86 $397,889 - $904,016
76,224 Added 186.44%
117,109 $764,000
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $467,315 - $784,992
40,885 New
40,885 $476,000
Q4 2020

Feb 03, 2021

SELL
$19.14 - $28.13 $382,800 - $562,600
-20,000 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$22.4 - $24.47 $448,000 - $489,400
20,000 New
20,000 $448,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $75M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.